Literature DB >> 18377425

Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.

Satoshi Fujii1, Atsushi Ochiai.   

Abstract

Overexpression of enhancer of zeste homolog 2 (EZH2), an epigenetic repressor, occurs in various malignancies and is associated with poor prognosis; however, the functional role of EZH2 overexpression in cancer versus non-cancerous tissue remains unclear. In this study, we found an inverse correlation between EZH2 and E-cadherin gene expression in gastric cancer cells. Knockdown of EZH2 by short interfering RNA in gastric cancer cells resulted in a restoration of the E-cadherin gene. We showed that the EZH2 complex existed with histone H3 and Lys27, which were methylated on E-cadherin promoter regions in gastric cancer cells. The restoration of E-cadherin was not involved in the change of the DNA methylation status in the E-cadherin promoter region. Immunofluorescence staining confirmed the expression of E-cadherin protein present in the cell membrane was restored after knockdown of EZH2, resulting in changing the cancer phenotype, such as its invasive capacity. In vivo, the relationship of inverse expression between EZH2 protein and E-cadherin protein was observed at the individual cellular level in gastric cancer tissue. This study provides into the mechanisms underlying the functional role of EZH2 overexpression in gastric cancer cells and a new modality of regulation of E-cadherin expression in silencing mechanisms of tumor suppressor genes. Our present study paves the way for exploring the blockade of EZH2 overexpression as a novel approach to treating cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18377425     DOI: 10.1111/j.1349-7006.2008.00743.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  30 in total

1.  Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma.

Authors:  Cheng Wang; Xiqiang Liu; Zujian Chen; Hongzhang Huang; Yi Jin; Antonia Kolokythas; Anxun Wang; Yang Dai; David T W Wong; Xiaofeng Zhou
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

2.  VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.

Authors:  Erick Riquelme; Milind Suraokar; Carmen Behrens; Heather Y Lin; Luc Girard; Monique B Nilsson; George Simon; Jing Wang; Kevin R Coombes; J Jack Lee; Waun Ki Hong; John Heymach; John D Minna; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

3.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer.

Authors:  Q Cao; J Yu; S M Dhanasekaran; J H Kim; R-S Mani; S A Tomlins; R Mehra; B Laxman; X Cao; J Yu; C G Kleer; S Varambally; A M Chinnaiyan
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

Review 4.  Polycomb and the emerging epigenetics of pancreatic cancer.

Authors:  Adrienne Grzenda; Tamas Ordog; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2011-06

5.  Histone modifiers in cancer: friends or foes?

Authors:  Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal:  Genes Cancer       Date:  2011-06

Review 6.  Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers.

Authors:  Ping Chi; C David Allis; Gang Greg Wang
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

7.  EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway.

Authors:  Te Liu; Lengchen Hou; Yongyi Huang
Journal:  Tumour Biol       Date:  2014-04-27

8.  Methylation Patterns of Lys9 and Lys27 on Histone H3 Correlate with Patient Outcome in Gastric Cancer.

Authors:  Yiping Li; Didi Guo; Rui Sun; Ping Chen; Qi Qian; Hong Fan
Journal:  Dig Dis Sci       Date:  2018-10-22       Impact factor: 3.199

9.  Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

Authors:  Andrei V Ougolkov; Vladimir N Bilim; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 10.  Role of microRNA-138 as a potential tumor suppressor in head and neck squamous cell carcinoma.

Authors:  Yi Jin; Dan Chen; Robert J Cabay; Anxun Wang; David L Crowe; Xiaofeng Zhou
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.